brief communication: magnetic immuno-detection of sars-cov … · 2020. 6. 2. · 15 specific...
Post on 27-Jan-2021
3 Views
Preview:
TRANSCRIPT
-
1
Article 1
Brief Communication: Magnetic Immuno-Detection of SARS-CoV-2 specific 2
Antibodies 3
Jan Pietschmann1,*, Nadja Vöpel1, Holger Spiegel1, Hans-Joachim Krause2 and Florian Schröper1 4
1 Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Forckenbeckstraße 6, 52074 Aachen, 5
2 Institute of Biological Information Processing, Bioelectronics IBI-3, Forschungszentrum Jülich, 52428 Jülich, 6
Germany 7
* Corresponding author 8
E-mail: jan.pietschmann@ime.fraunhofer.de (JP) 9
Abstract: 10
SARS-CoV-2 causes ongoing infections worldwide, and identifying people with immunity is 11
becoming increasingly important. Available point-of-care diagnostic systems as lateral flow assays 12
have high potential for fast and easy on-site antibody testing but are lacking specificity, sensitivity 13
or possibility for quantitative measurements. Here, a new point-of-care approach for SARS-CoV-2 14
specific antibody detection in human serum based on magnetic immuno-detection is described and 15
compared to standard ELISA. For magnetic immuno-detection, immunofiltration columns were 16
coated with a SARS-CoV-2 spike protein peptide. SARS-CoV-2 peptide reactive antibodies, spiked 17
at different concentrations into PBS and human serum, were rinsed through immunofiltration 18
columns. Specific antibodies were retained within the IFC and labelled with an isotype specific 19
biotinylated antibody. Streptavidin-functionalized magnetic nanoparticles were applied to label the 20
secondary antibodies. Enriched magnetic nanoparticles were then detected by means of frequency 21
magnetic mixing detection technology, using a portable magnetic read-out device. Measuring 22
signals corresponded to the amount of SARS-CoV-2 specific antibodies in the sample. Our 23
preliminary magnetic immuno-detection setup resulted in a higher sensitivity and broader 24
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprintthis version posted June 3, 2020. ; https://doi.org/10.1101/2020.06.02.131102doi: bioRxiv preprint
https://doi.org/10.1101/2020.06.02.131102
-
2
detection range and was four times faster than ELISA. Further optimizations could reduce assay 25
times to that of a typical lateral flow assay, enabling a fast and easy approach, well suited for point-26
of-care measurements without expensive lab equipment. 27
Keywords: COVID-19; frequency mixing technology; immunofiltration; magnetic beads, point-of-28
care diagnostic 29
1. Introduction 30
The new Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), is causing ongoing 31
worldwide infections, leading to an unprecedented pandemic. According to World Health 32
Organization (WHO), it is estimated that up to 82% of people with coronavirus disease 19 (COVID-33
19) are not aware that they are/were infected due to no or very mild symptoms [1]. COVID-19 34
symptoms can be noted comparable to common cold cough, rhinitis or fever up to harsh symptoms, 35
especially at elderly, such as respiratory problems with lung failure and death [2, 3]. Patients with 36
few or no symptoms in particular pose the greatest risk, as they can infect many more people via a 37
droplet infection [4]. Identifying people who were infected and have obtained immunity against 38
SARS-CoV-2 is becoming highly important. Besides valuable epidemiological information regarding 39
distribution and spreading behavior, detection methods would help to manage the currently imposed 40
restrictions and non-pharmaceutical measures. All people with confirmed immunity most probably 41
would have no risk to infect themselves and thus would not represent a risk of infection for others. 42
At a later point, serological assays would also be required to prove and monitor effectivity of 43
vaccination and longevity of the obtained immunity. Fast, cheap and easily applicable on-site testing 44
solutions will thus become increasingly important, but currently only few rapid test systems are 45
available. Lateral-flow-detection (LFD) approaches are easy to handle and results are gained after 10-46
15 min. However they are not quantitative, and their reliability, specificity and sensitivity is much 47
worse than that of lab-based assay formats based on enzyme-linked immunosorbent assay (ELISA). 48
In particular, specificity is a major challenge at currently available serological antibody tests. This 49
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprintthis version posted June 3, 2020. ; https://doi.org/10.1101/2020.06.02.131102doi: bioRxiv preprint
https://doi.org/10.1101/2020.06.02.131102
-
3
depends to a large extent on the antigen used in the test assays. Enveloped positive-stranded RNA 50
SARS-CoV-2 coronaviruses consist of five structural proteins, the spike glycoprotein (S), envelope 51
protein (E), membrane protein (M), the nucleocapsid protein (N) and a hemagglutinin esterase (HE). 52
The S-protein, a complex folded glycoprotein comprising two regions, S1 and S2, exhibits the highest 53
immunogenicity, has the most important role in host interaction, especially cell entry, and is also the 54
main target for neutralizing antibodies [5]. The proteins M, E and HE are only weakly immunogenic 55
and less suitable as targets for antibody diagnosis. Although the N protein is immunodominant, it is 56
not suitable for the specific analysis of the immune response against SARS-CoV-2 viruses due to its 57
high cross-reactivity with antibodies targeting related coronavirius strains [6, 7]. The company 58
Euroimmun AG, Lübeck, Germany offers two ELISA kits using a genetically modified N-protein 59
variant, which enables a more specific detection of antibodies already ten days after infection. 60
However, for highly specific detection of immune response against SARS-CoV-2, typically the S1 61
subunit of S-protein should be used. Currently, only few vendors offer these specific ELISA formats 62
using the S1 subunit of S-protein for specifically detecting SARS-CoV-2 antibodies [8, 9]. 63
Nevertheless, specific, sensitive and quantitative rapid tests applicable for a decentralized point-of-64
care (PoC) analysis are currently not available. 65
Magnetic Immuno-Detection (MInD) could be a powerful tool for PoC assay performance. MInD 66
employs immunofiltration columns (IFCs) containing a porous polyethylene matrix coated with 67
antigens retaining reactive antibodies from applied samples flushed through IFC by gravity flow. 68
Afterward, secondary antibodies specifically binding to the previously enriched antibodies are 69
applied, and subsequently specially functionalized magnetic particles (MNPs) are added, labelling 70
the secondary antibodies. After a washing step to elute unbound MNPs, IFSc are simply inserted into 71
the detection head of a portable magnetic read-out device in which retained MNPs are then detected 72
by means of frequency magnetic mixing detection technology (FMMD), using a low- and a high-73
frequency magnetic excitation field [10-17]. An alternately oscillating positive and negative magnetic 74
saturation of MNPs with a frequency of 2·f2 of 122 Hz is obtained when exposing the particle to a low 75
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprintthis version posted June 3, 2020. ; https://doi.org/10.1101/2020.06.02.131102doi: bioRxiv preprint
https://doi.org/10.1101/2020.06.02.131102
-
4
frequency magnetic field of frequency f2 = 61 Hz with an amplitude of a few millitesla [10]. Afterward, 76
the magnetization state of MNPs is probed by the high frequency magnetic excitation field with 77
f1 = 49 kHz. An iron oxide dose-dependent signal is obtained when the resulting mixing frequency 78
signal of f1 + 2·f2 is detected by a Faraday coil. The innermost coil is composed of two adjacent sections, 79
a so-called detection coil directly encircling the IFC, and a reversely wound empty reference coil, so 80
that the directly induced signal from the excitation coils is cancelled while retaining the nonlinear 81
response signal from the MNPs. A detailed description is found in Ref. [10]. An easy application of 82
this technique is guaranteed due to a direct visualization of the resulting measuring signal at the 83
touchscreen of our portable magnetic read-out device. 84
We here present a preliminary MInD proof-of-concept study in comparison to a standard 85
laboratory-based ELISA, demonstrating an improved detection of SARS-CoV-2 specific antibodies 86
spiked in human serum samples. We therefore employed a peptide originating from the SARS-CoV-2 87
Spike protein for IFC coating and antibody enrichment. Our approach might facilitate further 88
optimization to obtain a timely PoC setup for the detection of SARS-CoV-2 specific antibodies in human 89
blood samples. 90
91
2. Materials and Methods 92
2.1 Material and chemicals 93
NaCl, KCl, Na2HPO4 x 12 H20, KH2PO4, Na2(CO3), NaHCO3, Tris-HCL, MgCl2 x 6 H2O and 94
Albumin Fraction V (biotin-free) were acquired from Roth, Karlsruhe, Germany. Peroxidase substrate 95
were purchased from Merck KGaA, Darmstadt, Germany. 96
Coupling buffer was prepared by dissolving 15 mM Na2CO3 and 35 mM NaHCO3 in MilliQ-97
water, and pH was set to 9.6 with glacial acetic acid. Phosphate buffered saline (PBS) was prepared 98
by dissolving 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4 x 12 H2O and 1.5 mM KH2PO4 in MilliQ-99
water and setting pH to 7.4 with hydrochloric acid. As washing buffer, PBS with 0.05% (v/v) 100
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprintthis version posted June 3, 2020. ; https://doi.org/10.1101/2020.06.02.131102doi: bioRxiv preprint
https://doi.org/10.1101/2020.06.02.131102
-
5
Tween-20 was used. ELISA and MInD blocking buffer (BP) was prepared by adding 1% (w/v) 101
albumin fraction V (biotin free) in PBS. Alkaline Phosphatase (AP) buffer was prepared by dissolving 102
100 mM Tris-HCL, 100 mM NaCl and 5 mM MgCl2 x 6 H2O. Buffer was adjusted to pH 9.6 with HCl. 103
Serum sample from normal healthy human was collected in 2016 and stored at -20°C up to usage. 104
Immunofiltration columns (IFC) (ABICAP HP columns) were purchased from Senova 105
Gesellschaft für Biowissenschaft und Technik mbH, Weimar, Germany. High-binding 96-well 106
microtiter plates (article number 655061) were purchased form Greiner Bio-One GmbH, 107
Frickenhausen, Germany. 108
20-aminoacids SARS-CoV-2 spike protein peptide (article number ABIN1382273) derived from 109
the intracellular portion of S2 region of S-protein and corresponding polyclonal rabbit anti-SARS-110
CoV-2 spike protein peptide specific antibody (article number ABIN1030641) were acquired from 111
antibodies-online GmbH, Aachen, Germany. Biotin-SP (long spacer) AffiniPure Goat Anti-Rabbit IgG 112
(biotinylated GaR secondary antibody), Fc fragment specific (article number 111-065-008) as well as 113
Streptavidin-alkaline phosphatase (streptavidin-AP) (article number 016-050-084) were purchased 114
from Jackson ImmunoResearch Europe Ltd. UK. Streptavidin-functionalized magnetic particles with 115
a hydrodynamic diameter of 70 nm (synomag®-D, article number 104-19-701) were purchased from 116
micromod Partikeltechnologie GmbH, Rostock, Germany. 117
118
2.2 ELISA Procedure 119
For ELISA-based SARS-CoV-2 specific antibody detection, all following incubation steps were 120
performed at room temperature for 60 minutes unless stated otherwise. For coating, SARS-CoV-2 121
spike protein peptide was diluted in coupling buffer to a concentration of 2 µg·ml–1 and plated with 122
100 µl per well onto a high-binding 96-well microtiter plate and incubated. After 3 subsequent 123
washing steps with 200 µl PBS-T per well, each well was blocked with BP and incubated. After 124
washing, 100 µl of SARS-CoV-2 spike protein peptide specific antibody in concentrations ranging 125
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprintthis version posted June 3, 2020. ; https://doi.org/10.1101/2020.06.02.131102doi: bioRxiv preprint
https://doi.org/10.1101/2020.06.02.131102
-
6
from 1.22 ng·ml–1 to 5000 ng·ml–1 diluted in PBS or in human serum acquired in 2016, respectively, 126
were applied onto the microtiter plate. For blank measurements, PBS or human serum without spiked 127
antibody was employed. After incubation, the plate was washed again. Afterward, 100 µl of 128
biotinylated GaR secondary antibody, diluted 1:20,000 in PBS, was added to each well and incubated. 129
After washing three times with PBS-T, 100 µl of streptavidin-AP (diluted 1:1000 in PBS) was added 130
and incubated for 30 minutes. After washing, absorbance was measured using a Tecan Infinite M200 131
microplate reader at 405 nm after application of AP-substrate in AP-buffer and 5 minutes of 132
incubation in dark. 133
134
2.3 Preparation of MInD Immunifiltration Columns 135
For MInD, IFCs were equilibrated as described by Rettcher et al. (2015) [16]. After equilibration, 136
IFCs were coated with 500 µl of 2 µg·ml–1 SARS-CoV-2 spike protein peptide, diluted in coupling 137
buffer. After the solution flushed through by gravity flow, a 60 minutes incubation step was 138
performed. Afterward, IFCs were washed by applying 750 µl PBS. Subsequently, remaining binding 139
sites within the polyethylene filter matrix were blocked by applying twice 750 µl BP and an 140
incubation of 20 minutes after each application. After washing of the columns with 750 µl of PBS, 141
IFCs were ready to use for MInD SARS-CoV-2 spike protein peptide specific antibody detection. Pre-142
coated, ready-to use IFCs could be stored at 4°C for at least several days until they were used for the 143
assay. 144
145
2.4 MInD SARS-CoV-2 Spike Protein Peptide Specific Antibody Detection 146
For proof-of-concept MInD-based detection of antibodies against the SARS-CoV-2 Spike protein 147
peptide, dilutions of an antibody with known specificity for this Spike-protein peptide ranging from 148
1.22 ng·ml–1 to 5000 ng·ml–1 in PBS or in human serum acquired in 2016, respectively, were prepared 149
and applied onto the ready-to use IFCs. While the sample was flushed through the IFC by gravity 150
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprintthis version posted June 3, 2020. ; https://doi.org/10.1101/2020.06.02.131102doi: bioRxiv preprint
https://doi.org/10.1101/2020.06.02.131102
-
7
flow, SARS-CoV-2 specific antibodies were enriched within the matrix by specific binding to the 151
coated antigen. After 12 minutes of incubation, IFCs were washed with 750 µl PBS and 500 µl of 152
biotinylated GaR (diluted 1:2500 in PBS) were applied onto the columns, binding to retained 153
antibodies. After further incubation of 12 minutes, IFCs were washed again and 500 µl of 60 µg·ml–1 154
70 nm superparamagnetic streptavidin-functionalized magnetic particles were applied and flushed 155
through the IFCs and incubated for 12 minutes. After a final washing with 750 µl PBS, read-out was 156
done by inserting the columns into the portable magnetic reader, detecting the measuring signal in 157
mV as previously described by Rettcher et al. (2015) [16]. 158
159
Data Analysis 160
For ELISA as well as for MInD, data were analyzed using GraphPad Prism 8.0.0, and fitting with 161
a Hill slope was performed. Equations (1) and (2) were used to determine the limit of detection (LOD) 162
or maximum of detection (MOD), respectively, on the signal scale and Equation (3) was used for 163
calculation of those parameters on the concentration scale. SD denotes the standard deviation. 164
𝐒𝐢𝐠𝐧𝐚𝐥𝐋𝐢𝐦𝐢𝐭 𝐨𝐟 𝐃𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧 = 𝐀𝐯𝐞𝐫𝐚𝐠𝐞 𝐬𝐢𝐠𝐧𝐚𝐥𝐁𝐥𝐚𝐧𝐤 + 𝟑 ∙ 𝐒𝐃𝐁𝐥𝐚𝐧𝐤 (1) 165
166
𝐒𝐢𝐠𝐧𝐚𝐥𝐌𝐚𝐱𝐢𝐦𝐮𝐦 𝐨𝐟 𝐃𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧 = 𝐀𝐯𝐞𝐫𝐚𝐠𝐞 𝐬𝐢𝐠𝐧𝐚𝐥𝐬𝐚𝐭𝐮𝐫𝐚𝐭𝐞𝐝 𝐬𝐚𝐦𝐩𝐥𝐞𝐬 − 𝟑 ∙ 𝐒𝐃𝐬𝐚𝐭𝐮𝐫𝐚𝐭𝐞𝐝 𝐬𝐚𝐦𝐩𝐥𝐞𝐬 (2) 167
168
𝐂𝐨𝐧𝐜𝐞𝐧𝐭𝐫𝐚𝐭𝐢𝐨𝐧𝐒𝐚𝐦𝐩𝐥𝐞 = EC50 ∙ (𝐇𝐢𝐠𝐡𝐞𝐬𝐭 𝐒𝐢𝐠𝐧𝐚𝐥−𝐒𝐢𝐠𝐧𝐚𝐥𝐒𝐚𝐦𝐩𝐥𝐞
𝐒𝐢𝐠𝐧𝐚𝐥𝐒𝐚𝐦𝐩𝐥𝐞)
1
𝐻𝑖𝑙𝑙 𝑆𝑙𝑜𝑝𝑒 (3) 169
170
3. Results and Discussion 171
3.1. ELISA-based Calibration Experiments of SARS-CoV-2 Specific Antibody Detection 172
As reference method to our PoC MInD approach, a typical laboratory-based ELISA was performed 173
(Fig 1). After coating of ELISA microtiter plate with SARS-CoV-2 spike protein peptide and blocking 174
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprintthis version posted June 3, 2020. ; https://doi.org/10.1101/2020.06.02.131102doi: bioRxiv preprint
https://doi.org/10.1101/2020.06.02.131102
-
8
with BSA, SARS-CoV-2 spike protein peptide specific antibody was diluted in the range from 175
1.22 ng·ml–1 to 5000 ng·ml–1 in PBS-buffer or serum and applied into wells. After addition of 176
biotinylated GaR and subsequent labelling with streptavidin-AP, the ELISA plate was read out at 177
405 nm and obtained measuring values were used to generate calibration curves for SARS-CoV-2 178
specific antibody concentrations in PBS (Fig 1, black curve) and in human serum samples (Fig 1, red 179
curve). Blank values determined in PBS and serum were 0.085 AU ± 0.005 AU and 180
0.083 AU ± 0.001 AU, respectively, and were subtracted from sample values. Both curves recorded 181
with antigen diluted in PBS and human blood serum were almost identical. Based on a Hill fit, 182
calibration measurements in PBS with a LOD 3.4 ng·ml–1 and or LOD of 4.0 ng·ml–1 in human serum 183
were obtained (Fig 1). Both calibration measurements show saturation of measuring signals at 184
concentrations with 625 ng·ml–1 up to 5000 ng·ml–1. For calculation of maximum of detection, 185
the average measuring signal of samples with concentrations ranging from 625 ng·ml–1 up to 186
5000 ng·ml–1 was calculated and threefold SD was subtracted. Using equation 3, a MOD of 187
477 ng·ml–1 in PBS and of 312 ng·ml–1 in serum, respectively, could be determined. Following these 188
calibration measurements, it can be concluded, that with our laboratory-based ELISA, SARS-CoV-2 189
specific antibodies can be detected in range of 3.4 ng·ml–1 up to 477 ng·ml–1 in PBS-buffer or from 190
4.0 ng·ml–1 up to 312 ng·ml–1 in human serum samples, respectively. Typical IgG antibody 191
concentrations in human serum are approximately 10 mg·ml–1, and are significantly increasing after 192
antigenic stimulation of immune system [18]. For the whole assay, excluding coating and blocking 193
but including application of sample, secondary antibody, streptavidin-AP and substrate incubation, 194
a procedure time of 161 minutes was needed. This time is comparable to that of commercially 195
available ELISA test kits (e.g. Euroimmun 140 min). Comparing the sensitivity of commercially 196
available ELISA test kits with our standard ELISA will be possible when samples of COVID-19 197
patients are evaluated. A highly sensitive assay could detect antibodies at an early stage of infection, 198
whereas commercially test kits can detect IgG antibodies in patient samples against S1 subunit of 199
SARS CoV-2 S-protein in 75% of samples 10 to 20 days after infection (Euroimmun). 200
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprintthis version posted June 3, 2020. ; https://doi.org/10.1101/2020.06.02.131102doi: bioRxiv preprint
https://doi.org/10.1101/2020.06.02.131102
-
9
201
Fig 1. ELISA-based detection of SARS-CoV-2 spike protein specific antibody in PBS-buffer (black 202
curve) or spiked in human serum (red curve). Antibody was diluted to concentrations ranging from 203
1.22 ng·ml–1 up to 5000 ng·ml–1 in each matrix and applied onto 2 ng·ml–1 SARS-CoV-2 spike protein 204
peptide coated and BSA blocked microtiter plates. After addition of biotinylated secondary antibody, 205
streptavidin-AP was applied. Limit of detection (LOD) was calculated using non-linear Hill fit 206
(R2=0.997 for PBS-buffer and 0.996 in serum). Assay time of ELISA was 161 minutes. Each data point 207
represents mean ± SD (n = 4 for PBS-buffer and n = 3 for serum). 208
209
3.1. MInD-based Calibration Experiments for SARS-CoV-2 Specific Antibody Detection 210
Same calibration measurements employing dilutions of SARS-CoV-2 specific antibody were 211
done with our PoC MInD-based setup (Fig 2 and 3). Comparable to laboratory-based ELISA, the same 212
dilutions of SARS-CoV-2 spike protein peptide specific antibody in PBS-buffer (Fig 3, black curve) or 213
human serum (Fig 3, red curve) were applied after coating and blocking of IFC with SARS-CoV-2 214
spike protein peptide and BSA. After application of antibody dilutions, a 5-times shorter incubation 215
time of just 12 minutes compared to ELISA was performed. The reduction of incubation time could 216
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprintthis version posted June 3, 2020. ; https://doi.org/10.1101/2020.06.02.131102doi: bioRxiv preprint
https://doi.org/10.1101/2020.06.02.131102
-
10
be achieved due to a more efficient antibody enrichment. The surface for target binding within the 217
ABICAP immunofiltration column matrix is approximately 40-fold larger compared to the surface of 218
an ELISA well. Furthermore 500 µl of sample was applied and flushed through IFC, compared to just 219
100 µl of sample added to an ELISA microtiter plate well. Afterward, biotinylated GaR was applied 220
onto columns and magnetically labelled with 70 nm streptavidin-functionalized magnetic particles. 221
Again, incubation time of only 12 minutes each could be used due to the increased binding surface. 222
Finally, the IFCs were inserted into our portable magnetic read-out device which can be operated 223
using either an external power adapter or a portable battery, allowing a PoC diagnostic assay 224
procedure. A schematic overview of assay procedure is shown in Fig 2. 225
226
Fig 2. Proof-of-concept MInD assay setup using IFC coated with SARS-CoV-2 antigen. Assay steps 227
and assay time are indicated. IFCs were coated with commercial SARS-CoV-2 S-protein peptide and 228
blocked with BSA. Corresponding antibody was diluted either in PBS or spiked in human serum and 229
applied to IFCs. Biotinylated secondary antibodies were added, followed by application of 230
streptavidin-functionalized MNP. Finally, IFCs were inserted into the portable magnetic read-out 231
device. Measuring signal can be correlated to the amount of antibody in the sample and antibody titer 232
can be determined. Assay time of this preliminary MInD setup was 42 min which is approximately 233
four times faster than ELISA (161 min). 234
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprintthis version posted June 3, 2020. ; https://doi.org/10.1101/2020.06.02.131102doi: bioRxiv preprint
https://doi.org/10.1101/2020.06.02.131102
-
11
As shown in Fig 3, also with MInD-based approach SARS-CoV-2 specific antibody detection 235
calibration curves could be recorded using PBS-buffer or human serum, respectively. Particularly the 236
comparable calibration measurements in PBS or human serum demonstrate the negligible matrix 237
effect of human serum when using MInD. Compared to standard ELISA, a saturation of measurement 238
signal was observed only at samples with higher concentrations of 2500 ng·ml–1 and 5000 ng·ml–1. 239
Based on this, the average of these two samples was used for calculation of the MOD (Equation 2 and 240
3). By analyzing the range of detection, it can be seen that SARS-CoV-2 spike protein peptide specific 241
antibody can be detected in range of 2.95 ng·ml–1 up to 2040 ng·ml–1 in PBS and from 3.36 ng·ml–1 up 242
to 1810 ng·ml–1, demonstrating an at least 5-fold broader range of quantification in both PBS and 243
human serum with higher sensitivities compared to ELISA and perfectly matching nonlinear fit 244
(R2 =0.997 in PBS and R2 =0.993 in human serum). This significantly increased dynamic range 245
compared to ELISA demonstrates one major advantage enabling improved quantitative 246
measurements. 247
248
Fig 3. Proof-of-concept MInD-based SARS-CoV-2 specific antibody detection. IFCs were coated 249
with commercial 2 µg·ml–1 SARS-CoV-2 spike protein peptide and blocked with BSA. A 250
corresponding antibody was diluted either in PBS (black curves) or spiked in human serum (red 251
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprintthis version posted June 3, 2020. ; https://doi.org/10.1101/2020.06.02.131102doi: bioRxiv preprint
https://doi.org/10.1101/2020.06.02.131102
-
12
curves) and applied to IFCs. Biotinylated secondary antibodies were added, followed by application 252
of streptavidin-functionalized magnetic particles. Assay time of this preliminary MInD setup was 253
42 minutes (without column preparation). Limit of detection (LOD) was determined by help of 254
non-linear hill fit. Each data point represents mean ± SD (n = 2). 255
256
Furthermore, an approximately 4-fold reduction of assay time with PoC MInD approach 257
compared to ELISA demonstrates the high potential for fast assay procedure. In total, 42 minutes 258
procedure time was needed, resulting in a broader detection range in combination with lower 259
detection limits in both PBS and human serum. A further reduction of assay time could be achieved by 260
checking the required amount of washing steps and analyzing the achieved sensitivity when reducing 261
the incubation time to 5 minutes or less, as described by Rettcher et al. (2015) [16]. Additionally, Rettcher 262
and colleagues demonstrated a reduction of assay time by pre-functionalizing the MNPs with antigen-263
specific antibodies [16]. Here, MNPs can be pre-functionalized with secondary antibody, which would 264
result, in combination with previously mentioned optimization steps, in less assay steps with a 265
comparable assay time as PoC lateral flow assays (less than 20 minutes). 266
In this proof-of-concept experiment, a commercially available SARS-CoV-2 spike protein 267
peptide with corresponding antibody was used. If using this peptide for testing of patient samples, 268
there might be a high risk for false negative assay results, since patients may not have developed 269
antibodies against this peptide. Most preferably, other antigen variants derived from the highly 270
immunogenic S1-subunit of S-protein or a mixture of antigens of SARS-CoV-2 proteins should be 271
used for highly effective and specific enrichment of SARS-CoV-2 targeting antibodies. Especially for 272
demonstration of MInD specificity, control antigens derived from common cold human 273
coronaviruses (hCoV) as hCoV 229E, hCoV NL63, hCoV OC43, hCoV HKU1 or SARS-CoV and 274
MERS-CoV should be tested, confirming the enrichment of only SARS-CoV-2 specific antibodies. 275
Additionally, a multiplex detection of different MNPs, as demonstrated by Achtsnicht et al. (2019), 276
could be implemented for detection of multiple antibody subclasses in one assay [19]. By coupling 277
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprintthis version posted June 3, 2020. ; https://doi.org/10.1101/2020.06.02.131102doi: bioRxiv preprint
https://doi.org/10.1101/2020.06.02.131102
-
13
different secondary antibodies to MNPs, each type will label a specific antibody isotype, as e.g. IgA 278
and IgG, a course of infection could be visualized as well as the analysis of seroconversion would be 279
enabled. A further optimization of the magnetic read-out device towards a medical-diagnostic device 280
would then fulfill all requirements for use in medical field. To ensure correct sample allocation, the 281
magnetic reader can be equipped with a barcode scanner, and IFCs could be labelled with a patient-282
specific barcode. In combination with multiplex detection of several antibody isotypes, the MInD 283
approach would thus be ideally suited for the use in doctors' surgeries since our MInD assay has less 284
than 10% of the cost for typical ELISA equipment. Especially due to the possibility of performing the 285
PoC assay procedure with a single pipette, and the portable magnetic read-out device which can be 286
battery-operated, the MInD assay can also be used by service providers in the medical field and for 287
testing in elderly peoples’ and nursing homes or at airports, quickly identifying persons with existing 288
immunity. As soon as vaccination against SARS-CoV-2 is available, our approach could be employed 289
to monitor vaccination success and longevity of immunity by determining antibody titers. 290
4. Conclusions 291
We demonstrated for the first time a proof-of-concept MInD-based approach for rapid and highly 292
sensitive SARS-CoV-2 S-protein peptide specific antibody detection in spiked human serum. MInD 293
calibration experiments with a five-fold higher range of detection in combination with higher sensitivity 294
and a four-fold shorter assay time in comparison to a standard ELISA demonstrate the high potential 295
of MInD-based PoC SARS-CoV-2 specific antibody detection in serological samples. By using 296
appropriate SARS-CoV-2 antigens and a multiplex approach for simultaneous detection of e.g. IgA and 297
IgG antibodies reactive against SARS-CoV-2, the state of infection as well as a seroconversion could be 298
analyzed. Especially due to assay speed, low-cost and portable equipment, we conclude that the MInD-299
based assay would be ideally suited for PoC testing, identifying persons with existing immunity. 300
Additionally, our MInD approach could be employed for subsequent analysis of efficiency and for 301
monitoring the longevity of vaccination by determining antibody titers. 302
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprintthis version posted June 3, 2020. ; https://doi.org/10.1101/2020.06.02.131102doi: bioRxiv preprint
https://doi.org/10.1101/2020.06.02.131102
-
14
Author Contributions: Conceptualization, F.S. and J.P.; methodology, J.P. and N.V.; validation, J.P.; formal 303
analysis, J.P.; Resources, F.S., H.S. and H.J.K; investigation, F.S. and J.P.; data curation, J.P.; writing—original 304
draft preparation, J.P..; writing—review and editing, F.S., H.J.K, H.S. and N.V.; visualization, J.P.; supervision, 305
F.S.; project administration, F.S. 306
Funding: The author received no specific funding for this work. 307
Acknowledgments: The authors would like to thank Max Schubert for his helpful advices and support given in 308
discussions. 309
Competing interests: The authors declare no competing interests. 310
311
References 312
1. Kolifarhood G, Aghaali M, Mozafar Saadati H, Taherpour N, Rahimi S, Izadi N, et al. Epidemiological and 313
Clinical Aspects of COVID-19; a Narrative Review. Arch Acad Emerg Med. 2020;8(1):e41. 314
2. Zhu J, Ji P, Pang J, Zhong Z, Li H, He C, et al. Clinical characteristics of 3,062 COVID-19 patients: a meta-315
analysis. J Med Virol. 2020. 316
3. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 317
2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020. 318
4. Nikolich-Zugich J, Knox KS, Rios CT, Natt B, Bhattacharya D, Fain MJ. SARS-CoV-2 and COVID-19 in older 319
adults: what we may expect regarding pathogenesis, immune responses, and outcomes. Geroscience. 320
2020;42(2):505-14. 321
5. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of 322
the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181(2):281-92 e6. 323
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprintthis version posted June 3, 2020. ; https://doi.org/10.1101/2020.06.02.131102doi: bioRxiv preprint
https://doi.org/10.1101/2020.06.02.131102
-
15
6. Agnihothram S, Gopal R, Yount BL, Jr., Donaldson EF, Menachery VD, Graham RL, et al. Evaluation of 324
serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other 325
coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses. J Infect Dis. 326
2014;209(7):995-1006. 327
7. Khan S, Nakajima R, Jain A, de Assis RR, Jasinskas A, Obiero JM, et al. Analysis of Serologic Cross-328
Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray. 329
bioRxiv. 2020:2020.03.24.006544. 330
8. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients of novel 331
coronavirus disease 2019. Clin Infect Dis. 2020. 332
9. Krüttgen A, Cornelissen CG, Dreher M, Hornef M, Imöhl M, Kleines M. Comparison of four new 333
commercial serologic assays for determination of SARS-CoV-2 IgG. J Clin Virol. 2020. 334
10. Krause H, Wolters, N., Zhanga, Y., Offenhäusser, A., Miethe, P., Meyer, M.H.F. Hartmann, M., Keusgen, 335
M. Magnetic particle detection by frequency mixing for immunoassay applications. J Magn Magn Mater. 336
2007;311(1):436-44. 337
11. Achtsnicht S, Todter J, Niehues J, Teloken M, Offenhausser A, Krause HJ, et al. 3D Printed Modular 338
Immunofiltration Columns for Frequency Mixing-Based Multiplex Magnetic Immunodetection. Sensors (Basel). 339
2019;19(1). 340
12. Achtsnicht S, Neuendorf C, Fassbender T, Nolke G, Offenhausser A, Krause HJ, et al. Sensitive and rapid 341
detection of cholera toxin subunit B using magnetic frequency mixing detection. PLoS One. 2019;14(7):e0219356. 342
13. Meyer MH, Hartmann M, Krause HJ, Blankenstein G, Mueller-Chorus B, Oster J, et al. CRP determination 343
based on a novel magnetic biosensor. Biosens Bioelectron. 2007;22(6):973-9. 344
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprintthis version posted June 3, 2020. ; https://doi.org/10.1101/2020.06.02.131102doi: bioRxiv preprint
https://doi.org/10.1101/2020.06.02.131102
-
16
14. Martin H.F. Meyer H-JK, Markus Hartmann, Peter Miethe, Jürgen Oster, Michael Keusgen, . Francisella 345
tularensis detection using magnetic labels and a magnetic biosensor based on frequency mixing. J Magn Magn 346
Mater. 2007;311(1):259-63. 347
15. Meyer MH, Stehr M, Bhuju S, Krause HJ, Hartmann M, Miethe P, et al. Magnetic biosensor for the detection 348
of Yersinia pestis. J Microbiol Methods. 2007;68(2):218-24. 349
16. Rettcher S, Jungk F, Kuhn C, Krause HJ, Nolke G, Commandeur U, et al. Simple and portable magnetic 350
immunoassay for rapid detection and sensitive quantification of plant viruses. Appl Environ Microbiol. 351
2015;81(9):3039-48. 352
17. Pietschmann J, Spiegel H, Krause HJ, Schillberg S, Schroper F. Sensitive Aflatoxin B1 Detection Using 353
Nanoparticle-Based Competitive Magnetic Immunodetection. Toxins (Basel). 2020;12(5). 354
18. Ayres JA, Barraviera B, Calvi SA, Carvalho NR, Peraçoli MTS. Antibody and cytokine serum levels in 355
patients subjected to anti-rabies prophylaxis with serum-vaccination. Journal of Venomous Animals and Toxins 356
including Tropical Diseases. 2006;12:435-55. 357
19. Achtsnicht S, Pourshahidi AM, Offenhausser A, Krause HJ. Multiplex Detection of Different Magnetic 358
Beads Using Frequency Scanning in Magnetic Frequency Mixing Technique. Sensors (Basel). 2019;19(11). 359
360
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprintthis version posted June 3, 2020. ; https://doi.org/10.1101/2020.06.02.131102doi: bioRxiv preprint
https://doi.org/10.1101/2020.06.02.131102
top related